Digital Health And GLP-1 Focus Will Offer Opportunities Despite Risks

Key Takeaways

• Expansion into solutions for GLP-1 users and personalized wellness aims to capture new customers and drive recurring revenue.
  
• Digital enhancements, simplified programs, and coach network optimization target higher retention, lower acquisition costs, and stabilized margins.
  
• Heavy reliance on a shrinking coach network, narrow product focus, and rising competition threaten Medifast's revenue growth and long-term business model stability.

Catalysts

Through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States.

• Medifast is positioning its product portfolio to specifically address the needs of individuals using or transitioning off GLP-1 medications, a rapidly expanding market driven by increasing global obesity rates and heightened consumer focus on metabolic health; this may drive incremental customer acquisition and higher recurring revenue over the medium to long term.
  
• The simplification of pricing and loyalty programs with the Premier+ auto-ship structure is designed to enhance client retention, extend customer lifetime value, and reduce promotional churn, supporting more consistent revenue streams and stabilizing net margins.
  
• Continued investment in digital infrastructure-such as app enhancements and improved data capabilities for coaches-enables broader online engagement and personalization at scale, directly leveraging the acceleration in e-commerce and digital health adoption, likely lowering customer acquisition costs and supporting margin expansion.
  
• Launches of new product lines (ACTIVE and ASCEND) tailored to differentiated customer segments (exercise-focused, maintenance phase, and GLP-1 users) and ongoing innovation efforts position Medifast to capture share within the fast-growing personalized nutrition and wellness space, driving average order value and future revenue growth.
  
• Focused initiatives to boost coach network productivity-via streamlined onboarding, incentives (EDGE program), and leadership development-are expected to reignite coach recruitment and engagement, reversing downward revenue trends and supporting long-term earnings growth.

Medifast Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Medifast's revenue will decrease by 15.7% annually over the next 3 years.
• Analysts are not forecasting that Medifast will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Medifast's profit margin will increase from 0.8% to the average US Personal Products industry of 5.6% in 3 years.
• If Medifast's profit margin were to converge on the industry average, you could expect earnings to reach $16.1 million (and earnings per share of $1.79) by about August 2028, up from $3.6 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 10.5x on those 2028 earnings, down from 36.6x today. This future PE is lower than the current PE for the US Personal Products industry at 21.0x.
• Analysts expect the number of shares outstanding to decline by 3.59% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.81%, as per the Simply Wall St company report.

Medifast Future Earnings Per Share Growth

Risks

• The number of active earning OPTAVIA coaches declined by over 32% year-over-year, and new coach acquisition also fell compared to the prior year, indicating challenges in recruiting and retaining the coach network essential for Medifast's MLM-dependent business model, which directly pressures future revenue and topline growth.
  
• Average revenue per coach and total quarterly sales both decreased year-over-year, driven by continued pressure on client acquisition and lower coach productivity, suggesting a shrinking customer base that could lead to further declines in overall revenues and net margins.
  
• Company commentary emphasized a "pared back budget" for company-led client acquisition and a reliance on coaches to drive growth; if coach-led marketing becomes less effective or faces higher turnover, escalating acquisition costs or persistent declines could further erode earnings.
  
• Medifast's heavy focus on a single program (OPTAVIA, alongside new but still limited lines like ASCEND/ACTIVE) and a lack of significant product diversification leaves the company vulnerable to sudden shifts in consumer preferences-such as increasing adoption of digital health, telemedicine, or fresh food solutions-which could negatively impact both recurring revenue and gross margin stability.
  
• Intensifying competition from GLP-1 medications (which show high initial uptake despite drop-off rates), digital health platforms, and alternative nutrition models continues to reshape the weight-loss market; as these secular trends accelerate and consumers seek broader lifestyle services, Medifast's relatively narrow offering and MLM approach may lose share, putting sustained pressure on revenue growth and long-term earnings.

Valuation

• The analysts have a consensus price target of $15.0 for Medifast based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $287.4 million, earnings will come to $16.1 million, and it would be trading on a PE ratio of 10.5x, assuming you use a discount rate of 7.8%.
  
• Given the current share price of $12.96, the analyst price target of $15.0 is 13.6% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.